Multiple sclerosis treatments that repair damage to the brain could be developed thanks to new research.
Cambridge researchers developing new therapies as part of a collaborative programme with industry.
Alemtuzumab, a drug previously used to treat a type of leukaemia, shown to help people with early multiple sclerosis who relapsed on previous drugs...
Proof of principle study suggests the age-associated decline of the remyelination process is reversible.
Phase III clinical trials for new MS drug very positive.
Cohesion, collaboration and clinical impact are the watchwords of a new phase of stem cell research in Cambridge.
Critical insight provided into the disease mechanisms behind multiple sclerosis.
The path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to...
Insight could lead to new therapies to repair damage caused by MS.
Cambridge neurologists have shown that an antibody used to treat leukaemia also limits and repairs the damage in multiple sclerosis.
